Originally composed of autologous melanoma cells combined with two modified allogeneic cell lines expressing interleukin 6 (IL-6) and its soluble gp80 receptor (sIL-6R), early clinical studies in human melanoma patients were initiated in 1995, marking one of the pioneering gene therapy clinical trials globally. Here, IL6R is linked to melanoma.